Skip to navigation Skip to Content
Join a world-class health system. Find jobs

Marshfield Clinic Health System first in Wisconsin to offer new heart failure treatment

​Jan. 6, 2020

Marshfield Clinic Health System is the first health care system in Wisconsin and only the second in the Midwest to implant what is deemed as the world's first neuromodulation device for heart failure treatment.

Barostim Neo is a Food and Drug Administration-approved device which uses a novel mechanism to improve cardiovascular function. This pacemaker-like device is designed to electrically activate the baroreflex, the body's main cardiovascular reflex, signaling the brain to regulate cardiovascular function. Barostim Therapy activates baroreceptors in the wall of the carotid artery and stimulates the afferent and efferent pathways of the autonomic nervous system. The brain responds to the therapy by modulating efferent pathways, to relax blood vessels, slow the heart rate and reduce fluid in the body via improved kidney function.

Electrophysiologist Dr. Sanjay Kumar and Vascular Surgeon Dr. Tahlia Weis successfully performed the first two procedures at Marshfield Medical Center in Marshfield.

"We are very excited to bring this innovative and cutting edge technology that will address the unmet needs in cardiovascular diseases in the community," said Harry Singh, Cardiovascular service line administrator.

The placement of the Barostim Neo requires a minimally-invasive procedure under general anesthesia and can be done in an electrophysiology laboratory or catheterization lab as an outpatient procedure. The patients are usually discharged the same day or the next day. Physiological effects include lower heart rate and lower blood pressure.

"This technology will improve patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapy," said Dr. Milind Shah, medical director, Cardiovascular service line. "Patients can experience an improved quality of life and a greater ability to do simple exercises, such as walking without discomfort."

Designed to address a significant unmet medical need in heart failure, the Barostim Neo was one of the first therapies to receive the FDA's coveted Breakthrough Device Designation. This distinction is reserved for unique therapies that are intended to treat a life-threatening or irreversibly debilitating disease where there is no available treatment alternative.

To refer a patient or request a consultation call Marshfield Medical Center-Marshfield Cardiology at 715-387-5301 or Marshfield Medical Center-Weston Cardiology at 715-393-1220.

 


 Media Relations

John Gardner
Marshfield Clinic Health System Director of Communications
715 221-8659
gardner.john@marshfieldclinic.org

Jeff Starck
Media Relations Specialist - Marshfield, Wausau/Weston
715 389-4978
starck.jeffrey@marshfieldclinic.org

Amber Weldon
Regional Marketing and Public Relations Specialist - Minocqua, Park Falls
715 358-1320
weldon.amber@marshfieldclinic.org

Matt Schneider
Regional Communications Manager - Eau Claire
715 858-4427
schneider.matthew@marshfieldclinic.org

Christy Moravitz
Communications Specialist - Rice Lake
715 236-6409
moravitz.christy@lakeviewmedical.org

Dan Baulch
Media Communications Specialist - Beaver Dam
920 887-4152
dbaulch@bdch.org

Candy Marg
Community Relations Manager - Neillsville
715 743-8423
marg.candace@marshfieldclinic.org

Becca Baader
Communications Specialist - Ladysmith
715-532-1284
baader.rebecca@marshfieldclinic.org